Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Levis

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia|May 29, 2024
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibitionRuiqi Zhu, Courtney M Shirley, S Haihua Chu, et al.
Blood Advances|September 8, 2018
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamideLaura K Schoch, Kenneth R Cooke, Nina D Wagner-Johnston, et al.
Blood|October 29, 2008
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLZhihong Zeng, Yue Xi Shi, Ismael J Samudio, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2021
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
American Journal of Hematology|July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid LeukemiaMaro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Blood|July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsMark Levis, Patrick Brown, B Douglas Smith, et al.
Journal of Clinical Pharmacology|June 30, 2020
Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid LeukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Blood Neoplasia|September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AMLVinod A Pullarkat, Mark Levis, James McCloskey, et al.
Blood Advances|March 19, 2024
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemiaMark Levis, Alexander Perl, Gary Schiller, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia|May 29, 2024
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibitionRuiqi Zhu, Courtney M Shirley, S Haihua Chu, et al.
Blood Advances|September 8, 2018
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamideLaura K Schoch, Kenneth R Cooke, Nina D Wagner-Johnston, et al.
Blood|October 29, 2008
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLZhihong Zeng, Yue Xi Shi, Ismael J Samudio, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2021
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
American Journal of Hematology|July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid LeukemiaMaro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Blood|July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsMark Levis, Patrick Brown, B Douglas Smith, et al.
Journal of Clinical Pharmacology|June 30, 2020
Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid LeukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Blood Neoplasia|September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AMLVinod A Pullarkat, Mark Levis, James McCloskey, et al.
Blood Advances|March 19, 2024
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemiaMark Levis, Alexander Perl, Gary Schiller, et al.
Pageof 10